Drug Trial Radar · NCT07230652
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 20, 2025
Primary completion
Dec 31, 2025
Study completion Feb 28, 2026
Sponsor
- Lead sponsor
- Luye Pharma Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable schizophrenia.
Conditions
- Schizophrenia
- Alzheimer's Disease Psychosis
Interventions
LY03020Drug
administered orally
PlaceboDrug
administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs) and serious adverse events (SAEs).Time frame: up to Day 11
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing AnDing Hospital Capital Medical University
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.